 - Company Closed a 31.5M equity offering in April 2021; provides cash runway into 2023 - Plan to initiate Phase 2 trial with NM-002 in SBS with total stool output as the primary endpoint in Q2 following FDA guidance - Announced a collaboration with the Celiac Disease Foundation CDF to support clinical trial enrollment in 9 Meters Phase 3 study, CeDLara, for larazotide in celiac disease RALEIGH, NC ACCESSWIRE May 13, 2021 9 Meters Biopharma, Inc. NASDAQ:NMTR, a clinical-stage company focused on rare and unmet needs in gastroenterology, today provided an overview of its recent achievements and reported its financial results for the first quarter ended March 31, 2021. Key Business Highlights In April, the Company closed a public offering of 34.5 million shares of common stock, inclusive of the full overallotment option exercised by the underwriters. 